Literature DB >> 17551515

Intracellular amyloid-beta in Alzheimer's disease.

Frank M LaFerla1, Kim N Green, Salvatore Oddo.   

Abstract

The primal role that the amyloid-beta (Abeta) peptide has in the development of Alzheimer's disease is now almost universally accepted. It is also well recognized that Abeta exists in multiple assembly states, which have different physiological or pathophysiological effects. Although the classical view is that Abeta is deposited extracellularly, emerging evidence from transgenic mice and human patients indicates that this peptide can also accumulate intraneuronally, which may contribute to disease progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17551515     DOI: 10.1038/nrn2168

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN: 1471-003X            Impact factor:   34.870


  655 in total

1.  Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries.

Authors:  M Medecigo; K Manoutcharian; V Vasilevko; T Govezensky; M E Munguia; B Becerril; A Luz-Madrigal; L Vaca; D H Cribbs; G Gevorkian
Journal:  J Neuroimmunol       Date:  2010-05-06       Impact factor: 3.478

2.  Inhibitors of catalase-amyloid interactions protect cells from beta-amyloid-induced oxidative stress and toxicity.

Authors:  Lila K Habib; Michelle T C Lee; Jerry Yang
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

3.  Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease.

Authors:  Géraldine Poisnel; Anne-Sophie Hérard; Nadine El Tannir El Tayara; Emmanuel Bourrin; Andreas Volk; Frank Kober; Benoit Delatour; Thierry Delzescaux; Thomas Debeir; Thomas Rooney; Jésus Benavides; Philippe Hantraye; Marc Dhenain
Journal:  Neurobiol Aging       Date:  2011-11-12       Impact factor: 4.673

Review 4.  Cancer and neurodegenerative disorders: pathogenic convergence through microRNA regulation.

Authors:  Liqin Du; Alexander Pertsemlidis
Journal:  J Mol Cell Biol       Date:  2011-01-28       Impact factor: 6.216

5.  A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease.

Authors:  Rashid Deane; Itender Singh; Abhay P Sagare; Robert D Bell; Nathan T Ross; Barbra LaRue; Rachal Love; Sheldon Perry; Nicole Paquette; Richard J Deane; Meenakshisundaram Thiyagarajan; Troy Zarcone; Gunter Fritz; Alan E Friedman; Benjamin L Miller; Berislav V Zlokovic
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

6.  Single-cell mechanics provides a sensitive and quantitative means for probing amyloid-beta peptide and neuronal cell interactions.

Authors:  Valentin Lulevich; Christopher C Zimmer; Hyun-seok Hong; Lee-way Jin; Gang-yu Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

Review 7.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

8.  Olfactory epithelium amyloid-beta and paired helical filament-tau pathology in Alzheimer disease.

Authors:  Steven E Arnold; Edward B Lee; Paul J Moberg; Lauren Stutzbach; Hala Kazi; Li-Ying Han; Virginia M Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

9.  Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease.

Authors:  H N Dawson; V Cantillana; M Jansen; H Wang; M P Vitek; D M Wilcock; J R Lynch; D T Laskowitz
Journal:  Neuroscience       Date:  2010-04-29       Impact factor: 3.590

Review 10.  Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12.

Authors:  Paula Morales; Israa Isawi; Patricia H Reggio
Journal:  Drug Metab Rev       Date:  2018-02-01       Impact factor: 4.518

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.